Sign In
Buy RYTM
$99.25
-6.49 (-6.14%)
At Close: Jul 31, 2026
Rhythm Pharmaceuticals, Inc. (RYTM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
02:04pm, Tuesday, 09'th Sep 2025
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 11:30 AM EDT Company Participants David Meeker - Chairman, President & CEO Confere
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
04:01pm, Wednesday, 27'th Aug 2025
BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
04:01pm, Wednesday, 20'th Aug 2025
– U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- – European Medicines Agency accepts and validates submission for Type
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript
05:26pm, Tuesday, 05'th Aug 2025
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants David Connolly - Head of Investor Relations & Corporate Communications David
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
09:11am, Tuesday, 05'th Aug 2025
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.55 per share a year ago.
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update
07:00am, Tuesday, 05'th Aug 2025
-- Second quarter 2025 net product revenue from global sales of IMCIVREE ® (setmelanotide) of $48.5 million -- -- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesi
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline
11:10am, Tuesday, 29'th Jul 2025
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
04:01pm, Tuesday, 22'nd Jul 2025
BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar
Rhythm Pharmaceuticals CFO Sells 42,120 Shares
10:45am, Friday, 18'th Jul 2025
Smith Hunter C, Chief Financial Officer of Rhythm Pharmaceuticals (RYTM -0.04%), reported mixed transactions totaling 42,120 shares on July 9, 2025, as disclosed in an SEC Form 4 filing, resulting in
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
06:00pm, Saturday, 12'th Jul 2025
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelano
Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market
03:39pm, Thursday, 10'th Jul 2025
Rhythm Pharmaceuticals, Inc.'s IMCIVREE and new oral MC4R agonist, bivamelagon, show strong efficacy in rare obesity disorders, especially hypothalamic obesity (HO). HO represents a blockbuster market
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
12:11pm, Thursday, 10'th Jul 2025
Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.
Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar?
11:05am, Thursday, 10'th Jul 2025
Rhythm Pharmaceuticals (RYTM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further streng
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock
06:21am, Thursday, 10'th Jul 2025
BOSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patien
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
04:16pm, Wednesday, 09'th Jul 2025
BOSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patien
